HOW PERJETA IS GIVEN BEFORE SURGERY

PERJETA works with Herceptin® (trastuzumab) and docetaxel to fight HER2+ breast cancer

PERJETA is given every 3 weeks, on the same day as Herceptin and docetaxel, and during the same visit. PERJETA is given as an intravenous infusion (IV), which means that medication is administered directly and slowly into the bloodstream through a vein.

How does neoadjuvant treatment with PERJETA begin?

You and your doctor may decide that neoadjuvant treatment (before breast cancer surgery) with PERJETA is appropriate for you. PERJETA is part of an FDA-approved neoadjuvant treatment course for HER2+ early breast cancer, along with Herceptin and docetaxel, that may last up to 18 weeks before surgery. You will continue with Herceptin-based treatment after breast cancer surgery (also known as adjuvant treatment).

What is a neoadjuvant treatment course?

Possible courses of PERJETA-based treatment before surgery

PERJETA Neoadjuvant Treatment Pathway

These are possible treatment plans that include PERJETA. You and your doctor will determine a treatment plan that is appropriate for you.

Treatment before surgery: Course usually given every 3 weeks

PERJETA Neoadjuvant Dosing Phases

How long a treatment course may take

  • When you are getting treatment, PERJETA, Herceptin, and docetaxel will be given one at a time
  • There may be a waiting period of 30–60 minutes between infusions
  • Infusion time may vary from person to person depending on tolerability
  • After each medicine is given, your doctor or nurse will wait 30–60 minutes to check for any infusion or allergic reactions
  • They may adjust, delay, or stop treatment if a reaction occurs

What is a complete treatment course?

PERJETA is a medication that works with other medications to fight cancer.

Before breast cancer surgery:

  • PERJETA is given with Herceptin and docetaxel
  • Additional chemotherapy treatments may also be added
  • Treatment may be scheduled to last up to 18 weeks

After breast cancer surgery:

  • Herceptin will be continued after surgery to complete 1 full year of treatment
  • Sometimes traditional chemotherapy is also given with Herceptin after surgery
PERJETA Neoadjuvant Treatment Timeline

PERJETA for HER2+ early breast cancer before surgery

See the potential benefits and risks associated with PERJETA-based treatment for HER2+ early breast cancer.

Support for patients

If you have been diagnosed with HER2+ breast cancer, information and resources are available along your treatment journey.